SynthesisBMC oral health2025
Effect of platelet-derived bone enhancers used as adjuncts to deproteinized bovine bone matrix in maxillary sinus floor elevation: a systematic review and meta-analysis.
Synthesis in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical, radiographic and histomorphometry evaluation of the osteogenic potential of Schneiderian membrane after graftless maxillary sinus augmentation: a randomized controlled clinical trial.BMC oral health · 2026Trial
- Partially Demineralized Acellular Bovine Bone Matrix Supports for Bone Healing In Vivo.Journal of functional biomaterials · 2026Article
- Xenografts and platelet-rich fibrin impact on maxillary sinus augmentation: A comparative clinical histomorphometric study.Bioinformation · 2026Article
- Xenograft-Induced Damage and Synechiae Formation in the Maxillary Sinus Mucosa: A Retrospective Histological Analysis in Rabbits.Dentistry journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe success of dental implant restoration is significantly influenced by the volume and density of alveolar bone in the surgical area. Maxillary sinus floor elevation (MSFE) surgery is a reliable method to increase residual bone height (RBH) before implantation. This study aimed to evaluate the impact of platelet-derived bone enhancers, namely platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and platelet-rich growth factor (PRGF), when used as adjuncts to deproteinized bovine bone matrix (DBBM) in MSFE on bone neoformation, implant stability, and implant survival.
methodsA systematic review and meta-analysis were conducted following the PRISMA guideline. Electronic databases, including PubMed, Embase, CENTRAL, Web of Science, Scopus, and Google Scholar, were searched up to February 2025. Randomized controlled trials (RCTs), and case-control studies assessing the effect of PRP/PRF/PRGF as an adjuvant to DBBM in MSFE were included. Mean difference (MD) or risk ratio (RR) was selected as the effect size to perform the meta analysis.
resultsSixteen studies met the inclusion criteria, involving 372 patients and 455 surgical procedures. The meta-analysis revealed a significant enhancement of bone neoformation (MD = 5.92, 95%CI: 2.17 ~ 9.67, p = 0.002) and reduced residual graft volume (MD = -1.93, 95%CI: -2.25 ~ -1.61, p < 0.001) when PRP/PRF/PRGF was added to DBBM. However, there was no significant difference in graft resorption rate, percentage of fibrous tissue, immediate implant stability, and implant survival rate, between the two groups. Subgroup analyses showed that PRF subgroup, and subgroups with 4 m or 6 m healing intervals and with DBBM particles of 0.25-1 mm are related to significantly enhanced bone neoformation; all subgroups except for the PRP subgroup are related to significantly decreased residual graft.
conclusionsThe addition of PRF or PRGF to DBBM in the first stage of MSFE significantly enhances new bone formation and reduces residual graft volume, providing a more reliable alveolar bone matrix for subsequent implant placement. No evidence support the application of PRP as an effective enhancer to DBBM in MSFE procedure. In addition, PRP/PRF/PRGF does not significantly affect the immediate stability or survival of implants in the second stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.